Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study
- 6 October 2017
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 78 (1), 100-106.e1
- https://doi.org/10.1016/j.jaad.2017.09.061
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Antipalúdicos en dermatología: mecanismo de acción, indicaciones y efectos secundariosActas Dermo-Sifiliograficas, 2014
- Antimalarials in Dermatology: Mechanism of Action, Indications, and Side EffectsActas Dermo-Sifiliográficas (English Edition), 2014
- Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)Annals Of The Rheumatic Diseases, 2012
- Cutaneous lupus erythematosus: Update of therapeutic options: Part IJournal of the American Academy of Dermatology, 2011
- Response to Antimalarial Agents in Cutaneous Lupus ErythematosusArchives of Dermatology, 2011
- Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trialJournal of the American Academy of Dermatology, 2011
- Treatment of Cutaneous LupusCurrent Rheumatology Reports, 2011
- APLASTIC ANÆMIA FOLLOWING MEPACRINE TREATMENT OF LUPUS ERYTHEMATOSUSThe Lancet, 1955
- FATAL APLASTIC ANEMIA FOLLOWING QUINACRINE THERAPY IN CHRONIC DISCOID LUPUS ERYTHEMATOSUSJAMA, 1953
- APLASTIC ANEMIA IN SOLDIERS TREATED WITH ATABRINE (QUINACRINE)The American Journal of the Medical Sciences, 1946